Wednesday 29 November 2016: Poster Sessions: Molecular targeted agents I: Poster (Board P046)
TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants